Thursday - December 11, 2025
FDA Issues Warning Letter to Celularity
December 10, 2025
WASHINGTON, Dec. 10 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to Celularity Inc. from the Office of Compliance and Biologics Quality:

* * *

Recipient: Robert J. Hariri, M.D., Ph.D, Founder, Chairman & CEO, Celularity, Inc, 170 Park Avenue, Florham Park, NJ 07932, United States, robert.hariri@celularity.com

Issuing Office: Office of Compliance and Biologics Quality, United States< . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products